BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available electronically through PubMed (available at: http://www.ncbi.nlm.nih.gov/pubmed/23325450 ) and are expected to be published in the print issue of the American Journal of Cardiovascular Drugs in February 2013.
Amarin Announces Publication Of Additional Inflammatory Marker Data From MARINE And ANCHOR Phase 3 Clinical Trials In The American Journal Of Cardiovascular Drugs
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts